Teva Pharma Industries Stock In The News

TEVA Stock  USD 13.98  0.10  0.71%   
The overall news coverage of Teva Pharma Industries from major news outlets shows solid bullish sentiment on 8 news articles, blog posts, and TV commentaries analyzed in the last few months. Our overall analysis of Teva Pharma's news coverage and content from conventional and social sources shows investors' bearish mood towards Teva Pharma Industries. The specific impact of Teva Pharma news on its stock price will depend on a range of factors, including the nature and significance of the news report and investors' perceptions of Teva Pharma's overall financial health and prospects. It also depends on the type and quality of a news publisher.
  
Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using Teva Pharma headlines in addition to utilizing other, more conventional financial analysis modules. Check out Teva Pharma Backtesting and Teva Pharma Hype Analysis.

Teva Pharma Today Top News and Investor Outlook

Yahoo News
Unlocking Q1 Potential of Teva Pharmaceutical Industries (TEVA): Exploring Wall Street Estimates for Key Metrics
https://finance.yahoo.com/news/unlocking-q1-potential-teva-pharmaceutical-131521552.html
 Bullish
Yahoo News
Teva to Present at the 2024 Bank of America Healthcare Conference
https://finance.yahoo.com/news/teva-present-2024-bank-america-223000198.html
 Neutral
Yahoo News
Corcept Therapeutics Incorporated (NASDAQ:CORT) Q1 2024 Earnings Call Transcript
https://finance.yahoo.com/news/corcept-therapeutics-incorporated-nasdaq-cort-144819380.html
 Neutral
Yahoo News
U.S. Commercialization Agreement with Qu...
https://finance.yahoo.com/news/u-commercialization-agreement-quallent-drive-080000050.html
 Bullish
Yahoo News
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
https://finance.yahoo.com/news/1-u-supreme-court-rejects-153720025.html
 Bullish
Yahoo News
11 Best Low Price Pharma Stocks To Invest In
https://finance.yahoo.com/news/11-best-low-price-pharma-143958005.html
 Bullish
Yahoo News
Zacks Industry Outlook Highlights Teva, Dr. Reddy's and Viatris
https://finance.yahoo.com/news/zacks-industry-outlook-highlights-teva-100000907.html
 Bullish
Yahoo News
3 Generic Drug Stocks to Watch Amid Challenging Market Prospects
https://finance.yahoo.com/news/3-generic-drug-stocks-watch-151200623.html
 Bullish
Yahoo News
Alvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)
https://finance.yahoo.com/news/alvotech-teva-announce-u-fda-214300976.html
 Neutral
Yahoo News
Teva’s New Real-World Evidence Presented...
https://finance.yahoo.com/news/teva-real-world-evidence-presented-120000842.html
 Neutral

Teva Pharma Industries Past News Timeline

Popular news outlets such as MarketWatch, Bloomberg, or Reuters provide Teva and other traded companies coverage. We help investors stay connected with Teva headlines for the 6th of May to make an informed investment decision based on correlating the impacts of news items on Teva Stock performance. Please note that trading solely based on the Teva Pharma Industries hype is not for everyone as timely availability and quick action are needed to avoid losses.
Teva Pharma's linear event process diagram shows some of the filtered current and past headlines as well as many other corporate-specific events such as SEC filings, dividends, and regulatory reporting available to the public. This module can help Teva Pharma Industries investors visualize upcoming and past events in order to time the market based on Teva Pharma Industries noise-free hype analysis.
Teva Pharma stock price changes are notoriously difficult to predict based exclusively on its news coverage or social hype. Still, the Teva earnings-per-share ratio is a good starting point for gauging a company's future prospects. If a firm's EPS rises and meets or even beats consensus forecasts, its shares stand to increase. However, some very sophisticated investors can spot management manipulation of EPS through actions such as buybacks.
Far too much social signal, news, headlines, and media speculation about Teva Pharma that are available to investors today. That information is available publicly through Teva media outlets and privately through word of mouth or via Teva internal channels. However, regardless of the origin, that massive amount of Teva data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Teva Pharma news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Teva Pharma relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Teva Pharma's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Teva Pharma alpha.

Teva Largest EPS Surprises

Earnings surprises can significantly impact Teva Pharma's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
Reported
Fiscal Date
Estimated EPS
Reported EPS
Surprise
2001-04-24
2001-03-310.090.10.0111 
2000-05-04
2000-03-310.070.080.0114 
1998-05-11
1998-03-310.060.05-0.0116 
1998-02-24
1997-12-310.050.04-0.0120 
1996-11-11
1996-09-300.040.050.0125 
2002-04-29
2002-03-310.140.160.0214 
View All Earnings Estimates

Teva Pharma Stock Latest Headlines

Some academic researchers believe in a strong correlation between financial news and their impacts on the movements of stock prices. Macroaxis does not take a position on this subject and only provides tools that can help investors to time the market using conventional financial analysis. Below is the latest headlines and news related to Teva Pharma Industries Stock. Current markets are strongly bullish. About 83% of major world exchanges and indexes are currently up. See today's market update for more information.
Yahoo News
3rd of May 2024
Unlocking Q1 Potential of Teva Pharmaceutical Industries Exploring Wall Street Estimates f...
at finance.yahoo.com 
businesswire News
2nd of May 2024
Tevas 2023 Healthy Future Report Showcases Renewed Sustainability Strategy and Ambitious T...
at businesswire.com 
cnbc News
1st of May 2024
Healthy Returns Sales of Humira are plunging, but AbbVie has two promising successors
at cnbc.com 
Yahoo News
30th of April 2024
U.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Co...
at finance.yahoo.com 
Yahoo News
29th of April 2024
Global Active Pharmaceutical Ingredients Market Analysis Report 2024-2030 Synthetic API Se...
at finance.yahoo.com 
Yahoo News
24th of April 2024
Alvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Propose...
at finance.yahoo.com 
Yahoo News
22nd of April 2024
UPDATE 1-U.S. Supreme Court rejects Vanda Pharmaceuticals case over sleep-drug patents
at finance.yahoo.com 
Yahoo News
19th of April 2024
Acquisition by Amir Weiss of 22600 shares of Teva Pharma subject to Rule 16b-3
at finance.yahoo.com 
Yahoo News
16th of April 2024
Tevas New Real-World Evidence Presented at the 2024 AAN Annual Meeting Confirms Effectiven...
at finance.yahoo.com 
news
26th of March 2024
Experts say Medicaid rebate change is behind inhaler price cuts
at rollcall.com 
news
11th of March 2024
JPMorgan Chase Co. Upgrades Teva Pharmaceutical Industries to Neutral
at thelincolnianonline.com 

Teva Pharma Investors Sentiment

The influence of Teva Pharma's investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Teva. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Teva Pharma's public news can be used to forecast risks associated with an investment in Teva. The trend in average sentiment can be used to explain how an investor holding Teva can time the market purely based on public headlines and social activities around Teva Pharma Industries. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Teva Pharma's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Teva Pharma's and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Teva Pharma's news discussions. The higher the estimated score, the more favorable is the investor's outlook on Teva Pharma.

Teva Pharma Implied Volatility

    
  73.94  
Teva Pharma's implied volatility exposes the market's sentiment of Teva Pharma Industries stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Teva Pharma's implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Teva Pharma stock will not fluctuate a lot when Teva Pharma's options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Teva Pharma in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Teva Pharma's short interest history, or implied volatility extrapolated from Teva Pharma options trading.
When determining whether Teva Pharma Industries offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Teva Pharma's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Teva Pharma Industries Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Teva Pharma Industries Stock:

Complementary Tools for Teva Stock analysis

When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Bond Analysis
Evaluate and analyze corporate bonds as a potential investment for your portfolios.
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Balance Of Power
Check stock momentum by analyzing Balance Of Power indicator and other technical ratios
Portfolio Suggestion
Get suggestions outside of your existing asset allocation including your own model portfolios
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Options Analysis
Analyze and evaluate options and option chains as a potential hedge for your portfolios
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Commodity Directory
Find actively traded commodities issued by global exchanges
Is Teva Pharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Teva Pharma. If investors know Teva will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Teva Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
0.4
Earnings Share
(0.50)
Revenue Per Share
14.161
Quarterly Revenue Growth
0.148
Return On Assets
0.0454
The market value of Teva Pharma Industries is measured differently than its book value, which is the value of Teva that is recorded on the company's balance sheet. Investors also form their own opinion of Teva Pharma's value that differs from its market value or its book value, called intrinsic value, which is Teva Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Teva Pharma's market value can be influenced by many factors that don't directly affect Teva Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Teva Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Teva Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Teva Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.